Canine Patient Recruitment

As of August 21, 2015

If you would like additional information regarding a clinical trial, please contact us at:

Email: VeterinaryClinicalTrials@purdue.edu
Phone: (765) 496-9715
Fax: (765) 496-1108

If you believe your pet is eligible for a specific study, we recommend that you contact your veterinarian and request a referral. However a referral is not required to participate in a clinical trial.

To make an appointment at the Small Animal Hospital please call (765) 494-1107.

Behavior

Canine Aggression Study in Labrador Retriever, Beagle and Standard Poodle

- **Description**: This study is to compare genetic and behavior information between human directed aggressive dogs and non-aggressive (to both humans and animals) dogs in 3 different breeds to see if potential genetic and/or biomarkers may be identified.
- **Eligibility**: Pure bred Labrador Retrievers, Beagles or Standard Poodles that are either affected dogs (human aggressive dogs) or control dogs (no aggression toward humans or animals) are eligible.

Behavior information through questionnaire and blood sample are collected.

- **Financial Incentive**: no cost for collection of samples (blood). Blood collection can be also performed at the primary veterinarian office and ship to us (cost for blood collection and shipping will be covered).
- **Primary Investigator**: Dr. Niwako Ogata

Separation Anxiety disorder and Non-Separation anxiety disorder dogs

- **Description**: A study to develop biomarkers to assess anxiety disorders in dogs.
- **Eligibility**: Clinically healthy dogs that must be neutered/spayed and between the age of 1.5-7 years old. All participants (either separation anxiety dogs or non-anxious dogs) will be pre-screened for **Eligibility** through a questionnaire and a 30-minute video clip at home.
- **Financial Incentive**: no cost for collection of samples (blood).
- **Primary Investigator**: Dr. Niwako Ogata

Dogs with anxiety and/or fear related disorders
• **Description**: The purpose of this pilot study is to assess the efficacy of D-Cycloserine (DCS) in dogs with anxiety and/or fear related behavior disorders that are admitted to the Purdue Animal Behavior Service.

• **Eligibility**: Evaluation by the behavior service confirms the Eligibility of the study. Pre-bloodwork (CBC and chemistry profile) within 3 months must have already been performed or will be performed before the study by pet owners’ expense.

• **Financial Incentive**: Post-bloodwork (CBC and chemistry profile) 1 month after the last dose of DCS will be covered by the study. Three oral doses of DCS will be provided at no charge.
  - **Primary Investigator**: Dr. Niwako Ogata

### Medicine

**Dogs with chronic gastrointestinal disease**

• **Description**: A collaboration study with Texas A&M to investigate and ultimately control chronic gastrointestinal diseases in dogs.

• **Eligibility**: Any dog with chronic small intestinal enteropathies are eligible to enroll

• **Financial Incentive**: The following diagnostics are covered by the study: GI panel (TLI, folate, cobalamin), histopathology, and all shipping costs.

• **Primary Investigator**: Dr. Nolie Parnell

### Neurology

**MRI for dogs suspected to have brain tumors**

• **Description**: A study to develop MRI in the diagnosis of dogs with brain tumors.

• **Eligibility**: Any dog that is suspected to be suffering from a brain tumor. Examination by the Neurology & Neurosurgery service must confirm the suspicion of a brain tumor and Eligibility for the study. Bloodwork and chest radiographs (from within the last month) must have already been performed – these may be performed at the referring veterinarian office before the appointment at Purdue.

• **Financial Incentives**: The cost of the MRI is significantly reduced.

• **Primary Investigator**: Dr. Timothy Bentley

### Surgery and Metronomic Chemotherapy for Brain Tumors in Dogs

• **Description**: Combination surgery and chemotherapy for brain tumors in dogs, including a post-operative MRI and a repeat MRI at 3 months. Samples to test the chemotherapy concentrations will be taken during the study.

• **Eligibility**: Dogs that have been tentatively diagnosed with a brain tumor by MRI. Chest radiographs and bloodwork must also have been performed (within the last month). Other tests to assess general health may be required before dogs are eligible for enrollment.
• **Financial Incentives**: The brain tumor surgery, the chemotherapy, the bloodwork to monitor the chemotherapy and the two repeat MRIs will all be provided at no charge. (Dogs with inoperable brain tumors will be eligible for chemotherapy, bloodwork to monitor the chemotherapy and repeat MRI at 3 months, all provided at no charge).

• **Primary Investigators**: Dr. Timothy Bentley

---

**Oncology**

**Dogs with Transitional Cell Carcinoma**

• **Description**: This study is to determine the anti-tumor activity of Zebularine, and to select a dose that has antitumor effects, but does not cause unwanted side effects.

• **Eligibility**: Biopsy proof of TCC
  - Tumor mass in bladder or urethra measurable by ultrasound or other imaging tests
  - Expected survival ≥ 6 weeks
  - Normal liver function

• **Financial Incentive**: Zebularine will be provided at no cost to the owner.

• **Primary Investigator**: Dr. Debbie Knapp

**Dogs with Transitional Cell Carcinoma**

• **Description**: This pilot study is to determine the antitumor effects and the toxicity (or lack thereof) of a folate-targeted therapy.

• **Eligibility**: Biopsy diagnosis of naturally-occurring transitional cell carcinoma
  - Confirmed folate receptor expression in the tumor
  - Measurable cancer lesions
  - Expected survival ≥ 6 weeks

• **Financial Incentive**: Folate-tubulysin will be provided by a drug company. Most of the expenses related to administering and monitoring the treatment will be paid by the study funding agency. Pet owners will be asked to pay a portion for expenses not covered by the trial.

• **Primary Investigator**: Dr. Debbie Knapp

**Healthy/Normal Dogs AND dogs suspected or confirmed of having TCC that are admitted to the Purdue Veterinary Teaching Hospital**

• **Description**: This study is to learn more about the transitional cell carcinoma of the urinary bladder in order to develop effective strategies to prevent TCC or to treat it more effectively. We wish to compare the results from dogs who are normal or who have other non-cancer problems in their urinary tract.

• **Eligibility**: Healthy dogs or dogs with suspected or confirmed TCC that are at least one year of age that are admitted to the Purdue Veterinary Teaching Hospital

• **Financial Incentive**: no cost for collection of samples
Primary Investigator: Dr. Debbie Knapp

Dogs with Lymphoma

Description: This study involves the use of a new oral chemotherapy agent (MLN0415) which inhibits kappa B kinase (IKK); known to contribute to cancer progression and drug resistance in human lymphomas. This pilot study is to determine whether MLN0415 has activity against untreated or relapsed canine multicentric.

Eligibility: Biopsy confirmed high-grade multicentric lymphoma
- Measurable peripheral lymph nodes
- Expected survival time of at least 4 weeks
- Absence of significant symptoms of illness
- Absence of other serious diseases.

Financial Incentive: MLN0415 will be provided at no charge.

Primary Investigator: Dr. Michael Childress

Dogs with Lymphoma that have failed or relapsed following treatment

Description: The purpose of this pilot study is to assess the anti-tumor efficacy of carboplatin in dogs that have failed or relapsed following treatment of at least 1 other chemotherapy protocol

Eligibility: Biopsy confirmed high-grade multicentric lymphoma
- Cancer relapse following treatment
- Expected survival ≥ 4 weeks
- Normal CBC and serum creatinine ≤ 2 mg/dl

Financial Incentive: Carboplatin drug and tru-cut biopsy cost covered by research funds.

Primary Investigator: Dr. Michael Childress

Dogs with Lymphoma

Description: This multi-institutional trial, sponsored by the National Cancer Institute, assesses the safety and effectiveness of three newly developed chemotherapy agents when given to dogs with lymphoma.

Eligibility: Biopsy diagnosis of lymphoma
- Absence of clinical signs of illness
- Both newly diagnosed and relapsed lymphomas are eligible

Financial Incentive: Costs associated with this study will be provided. Additional financial support will be provided after your dog’s completion of this study for chemotherapy/treatment at the Veterinary Teaching Hospital.

Primary Investigator: Dr. Michael Childress

For more information on Oncology Clinical Investigations please visit their website at: http://www.vet.purdue.edu/pcop/
**Ophthalmology**

Golden Retriever Pigmentary Uveitis (PU)

- **Description**: A study to better understand the disease progression of PU and establish a DNA bank of samples from both affected and normal Golden Retrievers.
- **Eligibility**: Any purebred Golden Retriever
- **Financial Incentives**: There is no compensation for participation in this study. However the ocular examination is performed at no cost to you.
- **Primary Investigator**: Dr. Wendy Townsend

**Orthopedics**

Polyarthritis – folate-receptor targeted drug delivery

- **Description**: A study to evaluate a new folate-receptor drug complex for the treatment of immune mediated polyarthritis in dogs. The drug has strong anti-inflammatory activity, similar to the new rheumatoid arthritis drugs for humans.
- **Eligibility**: Dogs with naturally occurring immune mediated polyarthritis.
- **Financial Incentives**: All costs related to the diagnosis and rechecks through the 16 week recheck will be reimbursed to the owner. The owner is responsible for the cost of the initial visit for diagnosis. During this visit, the scintigraphy will be done free of charge. Once the diagnosis of immune mediated polyarthritis is made, the owner will be advised about Eligibility for enrollment.
- **Primary Investigator**: Dr. Gert Breur